Neuraxis Insider Buys Shares Worth $1,007,206, According to SEC Filing

Neuraxis Insider Bought Shares Worth $1,007,206, According to a Recent SEC Filing. Neuraxis is a medical technology company focused on developing neuromodulation therapies for chronic and debilitating conditions in children and adults. Its first product, IB-Stim, is a PENFS system for functional abdominal pain associated with IBS. Other indications in its pipeline include functional nausea in children, post-concussion syndrome in children, and cyclic vomiting syndrome in children.